参斛汤对前列腺癌患者术后病灶及血清microRNA-301a-3p水平的影响

The effect of Shenhu Decoction on postoperative tumor progression and serum microRNA-301a-3p level in patients with prostate cancer

摘要:

目的 探讨参斛汤对前列腺癌术后病灶进展及血清microRNA-301a-3p（miRNA-301a-3p）水平的影响。方法 选取2020年2月—2021年3月就诊于郑州大学第一附属医院的95例前列腺癌患者作为研究对象，按随机数表法分为对照组（47例）和研究组（48例）。患者均接受经尿道前列腺癌根治术，对照组术后接受常规化学治疗，研究组在对照组基础上增加参斛汤辅助治疗。比较两组患者术后病灶进展情况、血清学指标［前列腺特异性抗原（PSA）、游离前列腺特异性抗原（f-PSA）、游离前列腺特异抗原百分率（FPSAR）、血清肿瘤相关物质（TAM）］、免疫功能、不良反应等。结果 研究组局部病灶进展时间、远处转移时间较对照组长（P <0.05）。两组患者治疗前血清PSA、FPSAR、TAM、miR-301a-3p表达水平比较，差异无统计学意义（P >0.05），研究组FPSAR高于对照组（P <0.05），PSA、TAM、miR-301a-3p低于对照组（P <0.05）。两组患者治疗前CD3⁺、CD4⁺、CD8⁺、CD4⁺/CD8⁺水平比较，差异无统计学意义（P >0.05），研究组CD3⁺、CD4⁺、CD4⁺/CD8⁺较对照组高（P <0.05），CD8⁺较对照组低（P <0.05）。两组患者不良反应总发生率比较，差异无统计学意义（P >0.05）。结论 参斛汤用于前列腺癌术后辅助治疗可有效抑制病灶进展，提高患者免疫功能，抑制miR-301a-3p表达，但在减少术后化学治疗不良反应方面未见明显优势。

Abstract:

Objective To investigate the effect of Shenhu Decoction on postoperative tumor progression and serum microRNA-301a-3p level in patients with prostate cancer.Methods A total of 95 patients with prostate cancer treated in the First Affiliated Hospital of Zhengzhou University from February 2020 to March 2021 were included in this study. They were randomly divided into control group (47 cases) and study group (48 cases). Both groups received transurethral radical prostatectomy. After the operation, the control group received routine chemotherapy, while the study group additionally received Shenhu Decoction as an adjuvant treatment on the basis of the control group. The postoperative tumor progression, serological indicators [prostate-specific antigen (PSA), free prostate-specific antigen (f-PSA), free/total PSA ratio (FPSAR), and tumor-associated materials (TAM)], immune function and adverse reactions were compared between the two groups.Results The time to local tumor progression and distant metastasis in the study group was longer than that in the control group (P < 0.05). The serum levels of PSA, FPSAR, TAM, and microRNA-301a-3p before the treatment were not different between the two groups (P > 0.05). After the treatment, the serum levels of PSA, TAM and microRNA-301a-3p were lower, but the serum level of FPSAR was higher in the study group compared with the control group (P < 0.05). There was no difference in the frequency of CD3⁺ cells, CD4⁺ cells, CD8⁺ cells, and CD4⁺/CD8⁺ ratio before the treatment (P > 0.05). However, the frequency of CD3⁺ cells, CD4⁺ cells, and CD4⁺/CD8⁺ ratio were higher, but the frequency of CD8⁺ cells was lower in the study group relative to the control group after the treatment (P < 0.05). In addition, there was no significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05).Conclusions As a adjuvant therapy for prostate cancer, Shenhu Decoction can effectively slow the postoperative tumor progression, enhance the immune function of the patients, and inhibit the expression of microRNA-301a-3p. However, it shows no advantage in reducing the adverse reactions induced by postoperative chemotherapy.